Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070728 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A Phase 3 study, sponsored by EyePoint Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT05070728 is a Phase 3 study that was terminated before completion, run by EyePoint Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT05070728, a Phase 3 study, was terminated before completion, sponsored by EyePoint Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
Interventions
- DRUG Sham Injector
- DRUG FAI Insert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05070728
The ClinicalTrials.gov registry entry for NCT05070728 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Injector is the first listed.
NCT05070728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05070728 about?
NCT05070728 is a clinical study titled "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert". A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
What is the current status of trial NCT05070728?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2021-10-13. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT05070728?
The interventions under investigation include: Sham Injector (DRUG), FAI Insert (DRUG).
Who is sponsoring clinical trial NCT05070728?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.